MagSense® Applications & Pipeline

Molecularly targeted magnetism

MagSense® Clinical Pipeline

MagSense® products are disruptive – enabling molecular MRI for primary diagnosis & and staging, stand-alone diagnostics, and companion diagnostics.

Clinical Imaging

MagSense® HER2 Imaging Agent (MSH2IA)

MagSense® FR Imaging Agent (MSFIA)

MagSense® PSMA Imaging Agent (MSPIA)

Vascular Imaging Agent

Pancreatic
Cancer

DiscoveryPreclinical DevelopmentClinical Development
Phase 1 Complete
IND-enabling Nominee
In vivo PoC complete
In vivo PoC complete
Prestige Biopharma

Other Biomedical Applications

Hyperthermic
Tumor Ablation

Nanoparticle-based
Vaccines

Phase 1 on-going
Pre-commercial Supply
DiscoveryPreclinical DevelopmentClinical Development

Clinical Imaging

MagSense® HER2 Imaging Agent (MSH2IA)

Phase 1 Complete

MagSense® FR Imaging Agent (MSFIA)

IND-enabling Nominee

MagSense® PSMA Imaging Agent (MSPIA)

In vivo PoC complete

ContraMax® Vascular Imaging

In vivo PoC complete

Pancreatic Cancer

Prestiege Biopharma

Other Biomedical Applications

Hyperthermic Tumor Ablation

Phase 1 on-going

Nanoparticle-based Vaccines

Pre-commercial Supply
Visit MagSense® HER2 Clinical Trial

Disrupting Diagnostic Imaging

MagSense® technology enables a new era in functional imaging, promising more sensitivity and safer detection of cancers and other critical diseases. Specialized bio-safe magnetic nanoparticles are coated with tumor-targeting molecules that are able to circulate through normal blood flow or local injection. When bound to a tumor the MagSense® particles can then be detected by Magnetic Resonance Imaging scanners.
Learn more about MagSense®

MagSense® Pre-Clinical and Clinical Applications

Transforming precision medicine to make better-informed decisions for patients’ diagnosis and treatment.

Learn more about our partnerships

If you’re looking to become a strategic partner to help design and drive clinical development, learn more about our collaboration opportunities.

Strategic Partnerships